These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33211271)

  • 21. Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+Foxp3-negative T cells as a source of IL-10 in Leishmania major susceptibility.
    Nagase H; Jones KM; Anderson CF; Noben-Trauth N
    J Immunol; 2007 Aug; 179(4):2435-44. PubMed ID: 17675505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses.
    Arendse B; Van Snick J; Brombacher F
    J Immunol; 2005 Feb; 174(4):2205-11. PubMed ID: 15699153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response.
    Chakir H; Campos-Neto A; Mojibian M; Webb JR
    Microbes Infect; 2003 Apr; 5(4):241-9. PubMed ID: 12706437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-Adrenergic blockade protects BALB/c mice against infection with a small inoculum of Leishmania mexicana mexicana (LV4).
    García-Miss Mdel R; Mut-Martín MC; Góngora-Alfaro JL
    Int Immunopharmacol; 2015 Jan; 24(1):59-67. PubMed ID: 25461918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Therapeutic Effects of Curcumin-coated Gold Nanoparticle Against Leishmania Major Causative Agent of Zoonotic Cutaneous Leishmaniasis (ZCL): An In Vitro and In Vivo Study.
    Amini SM; Hadighi R; Najm M; Alipour M; Hasanpour H; Vosoogh M; Vosough A; Hajizadeh M; Badirzadeh A
    Curr Microbiol; 2023 Feb; 80(4):104. PubMed ID: 36781499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody.
    Heinzel FP; Maier RA
    Infect Immun; 1999 Dec; 67(12):6454-60. PubMed ID: 10569763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR; Kaufmann D; Campos-Neto A; Reed SG
    J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sambucus ebulus extract stimulates cellular responses in cutaneous leishmaniasis.
    Heidari-Kharaji M; Fallah-Omrani V; Badirzadeh A; Mohammadi-Ghalehbin B; Nilforoushzadeh MA; Masoori L; Montakhab-Yeganeh H; Zare M
    Parasite Immunol; 2019 Jan; 41(1):e12605. PubMed ID: 30472741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral treatment with zinc sulfate increases the expression of Th1 cytokines mRNA in BALB/c mice infected with Leishmania major.
    Afshari M; Riazi-Rad F; Khaze V; Bahrami F; Ajdary S; Alimohammadian MH
    Cytokine; 2016 May; 81():71-6. PubMed ID: 26896749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
    Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
    Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Codelivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice.
    Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A
    Parasite Immunol; 2016 Apr; 38(4):228-35. PubMed ID: 26868280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of negative air ions (NAIs) on Leishmania major: A novel tool for treatment of zoonotic cutaneous leishmaniasis (ZCL).
    Badirzadeh A; Najm M; Hemphill A; Alipour M; Hasanpour H; Masoori L; Karimi P
    PLoS One; 2022; 17(9):e0274124. PubMed ID: 36074764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice.
    Louis JA; Conceiçao-Silva F; Himmelrich H; Tacchini-Cottier F; Launois P
    Adv Exp Med Biol; 1998; 452():53-60. PubMed ID: 9889959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
    Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
    Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
    Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania major.
    De Freitas LA; Mbow LM; Estay M; Bleyenberg JA; Titus RG
    Parasite Immunol; 1999 May; 21(5):273-7. PubMed ID: 10320625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis.
    Afonso LC; Scott P
    Infect Immun; 1993 Jul; 61(7):2952-9. PubMed ID: 8514400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. F₁ cross-breed between susceptible BALB/c and resistant Swiss mice infected with Leishmania major exhibit an intermediate phenotype for lesion sizes and type 1 cytokines but show low level of total IgG antibodies.
    Kiige SG; Mutiso JM; Laban LT; Khayeka-Wandabwa C; Anjili CO; Ingonga J; Gicheru MM
    Scand J Immunol; 2014 May; 79(5):283-91. PubMed ID: 24498914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection.
    Arinola OG; Louis JS; Tacchini-Cottier F; Aseffa A; Salimonu LS
    Afr J Med Med Sci; 2005 Mar; 34(1):65-70. PubMed ID: 15971557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.